Rogers (ROG) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
November 4, 2016 8:26 AM EDTNeedham & Company reiterated a Buy rating on Rogers Corp (NYSE: ROG), and raised the price target to $75.00 (from $70.00), following the company's 3Q earnings report. ROG reported revenues of $165M and EPS of $0.95, above prior guidance for $150-160M and adjusted EPS of $0.69-0.79. Previous consensus... More
Genentech (RHHBY) Plans Presentation of New Actemra, Rituxan Data at 2016 ACR/ARHP Annual Meeting
November 2, 2016 6:27 AM EDTGenentech, a member of the Roche Group (OTC: RHHBY) announced that new data from Actemra (tocilizumab) and Rituxan (rituximab) will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 11-16, Washington, D.C. These data add to the significant body of evidence for Actemra and Rituxan in RA and other serious immune-mediated conditions including GCA, systemic sclerosis (SSc), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Advances in our scientific understanding behind immune pathways are guiding the development of potential new treatments for severe... More
Trading Radar for 11/2: Facebook (FB), Qualcomm (QCOM), Alibaba (BABA), Yelp (YELP), Allstate (ALL), Fitbit (FIT) Report
November 1, 2016 2:56 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:15am EDT
Earnings:
1-800-FLOWERS.com (NYSE: FLWS) - consensus loss $0.23
Alibaba (NYSE: BABA) - consensus EPS $0.69
Alkermes plc (Nasdaq: ALKS) - consensus loss $0.06
Allergan (NYSE: AGN) - consensus EPS $3.65
AmerisourceBergen (NYSE: ABC) - consensus EPS... More

